Antifungal susceptibilities of Cryptococcus neoformans

被引：44

作者：

Archibald, LK

Tuohy, MJ

Wilson, DA

Nwanyanwu, O

Kazembe, PN

Tansuphasawadikul, S

Eampokalap, B

Chaovavanich, A

Reller, LB

Jarvis, WR

Hall, GS

Procop, GW

机构：

[1] Ctr Dis Control & Prevent, Atlanta, GA USA

[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA

[3] Lilongwe Cent Hosp, Lilongwe, Malawi

[4] Bamrasnaradura Hosp, Nonthaburi, Thailand

[5] Duke Univ, Durham, NC 27706 USA

来源：

EMERGING INFECTIOUS DISEASES | 2004年 / 10卷 / 01期

关键词：

D O I：

10.3201/eid1001.020779

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Susceptibility profiles of medically important fungi in less-developed countries remain uncharacterized. We measured the MICs of amphotericin B, 5-flucytosine, fluconazole, itraconazole, and ketoconazole for Cryptococcus neoformans clinical isolates from Thailand, Malawi, and the United States and found no evidence of resistance or MIC profile differences among the countries.

引用

页码：143 / 145

页数：3

共 15 条

[1] Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients ≥15 years old, Bangkok
Archibald, LK
McDonald, LC
Rheanpumikankit, S
Tansuphaswadikul, S
Chaovanich, A
Eampokalap, B
Banerjee, SN
Reller, LB
Jarvis, WR
[J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) : 87 - 92
[2] A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: Implications for diagnosis and therapy
Archibald, LK
McDonald, LC
Nwanyanwu, O
Kazembe, P
Dobbie, H
Tokars, J
Reller, LB
Jarvis, WR
[J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) : 1414 - 1420
[3] Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998
Brandt, ME
Pfaller, MA
Hajjeh, RA
Hamill, RJ
Pappas, PG
Reingold, AL
Rimland, D
Warnock, DW
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3065 - 3069
[4] In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole
Davey, KG
Johnson, EM
Holmes, AD
Szekely, A
Warnock, DW
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (02) : 217 - 220
[5] Multicenter comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms
Espinel-Ingroff, A
Pfaller, M
Messer, SA
Knapp, CC
Killian, S
Norris, HA
Ghannoum, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) : 591 - 595
[6] In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs
Franzot, SP
Hamdan, JS
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) : 822 - 824
[7] Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe
Heyderman, RS
Gangaidzo, IT
Hakim, JG
Mielke, J
Taziwa, A
Musvaire, P
Robertson, VJ
Mason, PR
[J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) : 284 - 289
[8] Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994
Klepser, ME
Pfaller, MA
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (12) : 3653 - 3656
[9] CRYPTOCOCCOSIS IN THE ERA OF AIDS - 100 YEARS AFTER THE DISCOVERY OF CRYPTOCOCCUS-NEOFORMANS
MITCHELL, TG
PERFECT, JR
[J]. CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) : 515 - &
[10] National Committee for Clinical Laboratory Standards, 2002, REF METH BROTH DIL A

← 1 2 →